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Context: There is controversy regarding whether ob-
jective neurobiological abnormalities exist after inten-
sive antibiotic treatment for Lyme disease.
Objectives: To determine whether patients with a his-
tory of well-characterized Lyme disease and persistent
cognitive deficit show abnormalities in global or topo-
graphic distributions of regional cerebral blood flow
(rCBF) or cerebral metabolic rate (rCMR).
Design: Case-controlled study.
Setting: A university medical center.
Participants: A total of 35 patients and 17 healthy vol-
unteers (controls). Patients had well-documented prior
Lyme disease, a currently reactive IgG Western blot, prior
treatment with at least 3 weeks of intravenous cephalo-
sporin, and objective memory impairment.
Main Outcome Measures: Patients with persistent
Lyme encephalopathy were compared with age-, sex-, and
education-matched controls. Fully quantified assess-
ments of rCBF and rCMR for glucose were obtained while
subjects were medication-free using positron emission
tomography. The CBF was assessed in 2 resting room air
conditions (without snorkel and with snorkel) and 1 chal-
lenge condition (room air enhanced with carbon diox-
ide, ie, hypercapnia).
Results: Statistical parametric mapping analyses re-
vealed regional abnormalities in all rCBF and rCMR mea-
surements that were consistent in location across imaging
methods and primarily reflected hypoactivity. Deficits
were noted in bilateral gray and white matter regions, pri-
marily in the temporal, parietal, and limbic areas. Al-
though diminished global hypercapnic CBF reactivity
(P .02) was suggestive of a component of vascular com-
promise, the close coupling between CBF and CMR sug-
gests that the regional abnormalities are primarily meta-
bolically driven. Patients did not differ from controls on
global resting CBF and CMR measurements.
Conclusions: Patients with persistent Lyme encepha-
lopathy have objectively quantifiable topographic abnor-
malities in functional brain activity. These CBF and CMR
reductions were observed in all measurement condi-
tions. Future research should address whether this pat-
tern is also seen in acute neurologic Lyme disease.
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L YME DISEASE, A MULTISYS-temic infection caused by thespirochete Borrelia burgdor-feri, can affect many organsincluding the central ner-
vous system (CNS). While most patients
recover fully when treated with antibiot-
ics soon after infection, patients who are
treated months after the initial infection
may sustain ongoing problems with fa-
tigue, cognition, and pain despite receipt
of a standard course of antibiotics.1,2 These
patients have been described as having
chronic Lyme Disease or posttreatment
Lyme disease syndrome.3,4 Continuing
symptoms have been attributed to persis-
tent infection,3 pathogen-induced auto-
immunity,5 or unrelated processes such as
depression, somatization, fibromyalgia, or
chronic fatigue syndrome.4 Objective
markers of disease are needed.
Structural imaging studies with mag-
netic resonance imaging (MRI) in acute
neurologic Lyme disease have demon-
strated white matter hyperintensities on
T2-weighted images similar to those seen
in demyelinating or inflammatory disor-
ders.6,7 In patients with later-stage neuro-
logic Lyme disease, initial reports indi-
cated that these hyperintensities persist
after treatment, but are less prevalent or
severe.8 However, a recent age- and sex-
matched control study revealed that pa-
tients with later stage Lyme disease do not
have a higher frequency of white matter
hyperintensities or basal ganglia lesions.9
In functional imaging studies, hypoper-
fusion has been reported in small case se-
ries of patients with chronic Lyme dis-
ease using brain single-photon emission
computed tomography (SPECT). Charac-
terized by widely distributed multifocal
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areas of decreased perfusion in both cortical and sub-
cortical white matter, this pattern is typical of patients
with cerebral vasculitis or encephalitis.10 A case-control
study using technetium 99m SPECT compared cogni-
tively impaired patients with Lyme disease with older
healthy controls and found multifocal areas of hypoper-
fusion in the subcortical frontotemporal white matter and
basal ganglia as well as in the frontal cortex and cingu-
late gyrus.11 Another study compared posttreatment pa-
tients with Lyme disease with carefully matched ar-
chived controls using the fully quantitative xenon133
inhalation technique (external detector system).12 Sig-
nificant cerebral blood flow (CBF) reductions were noted
in compartment-modeled flows primarily reflecting white
matter perfusion, particularly in bilateral posterior tem-
poral and parietal lobes.
In the only prior study of brain metabolism in Lyme
disease, 23 patients received positron emission tomog-
raphy (PET) measurement of regional cerebral meta-
bolic rate (rCMR) for glucose.13 Qualitative clinical read-
ings revealed hypometabolism in 74% of the patients’
temporal lobes, but in a subset of these, the frontal and
parietal lobes were also affected. However, criteria for di-
agnosis of Lyme disease were unclear and this study did
not include matched healthy comparison subjects.
This limited literature suggests that while structural ab-
normalities are not likely to be found in chronic Lyme dis-
ease, regional functional abnormalities in rCBF and rCMR
may be seen. However, each of these functional studies had
design limitations that preclude definitive conclusions. Fur-
ther, no study has yet assessed both cerebral metabolism
and blood flow in the same set of patients.
The purpose of this study was to address the lack of sys-
tematicdataregardingrCBFandrCMRinpatientswithper-
sistent Lyme encephalopathy, a type of chronic Lyme dis-
easecharacterizedbycognitivedeficits thatpersistor return
after antibiotic treatment. In this study, carefullycharacter-
izedpatientswerecomparedwithage-, sex-, andeducation-
matchedhealthyvolunteers (controls)usingaseriesofPET
scans in both resting and hypercapnic conditions to obtain
full quantification of rCBF and rCMR in the same subjects.






to increase cerebral blood flow and highlight areas of inad-
equatevascularreserve.Aconsistentpatternofdeficitsacross
both blood flow and metabolic measurements would sug-
gest a primary dysfunction in metabolism, given the usual
closecouplingofmetabolismtoflow.Ifdeficitsoccurredpri-
marily during rCBF measurement or were significantly ac-
centuatedduringhypercapnia,thedysfunctionwouldbecon-
sidered largely vascular in origin.
METHODS
PARTICIPANTS
A sample of 35 patients and 17 controls participated in func-
tional brain imaging assessments prior to a placebo-controlled
clinical trial of the efficacy of intravenous ceftriaxone in pa-
tients. The patients historically met Center for Disease Con-
trol clinical and laboratory criteria for Lyme disease,14 had a
currently reactive IgG Western blot, prior treatment includ-
ing at least 3 weeks of intravenous cephalosporin, and memory
impairment. Memory impairment was defined by a demographi-
cally adjusted standardized T score on at least 1 index of the
Wechsler Memory Scale that was 1 or less SD below the popu-
lation mean (T score40).15 Patients were excluded who had
a non–Lyme disease–related medical or neurological condi-
tion that could explain the memory impairment. On the basis
of interviews using the Structured Clinical Interview for Diag-
nosis16 and applying DSM-IV criteria,17 patients were ex-
cluded if they currently or historically had any psychotic dis-
order. Patients with other current psychiatric disorders were
excluded if onset of the disorder preceded the onset of Lyme
disease. Controls had negative enzyme-linked immunosor-
bent and Western blot assays for Lyme disease and no evi-
dence of memory impairment, a neurologic disorder, or a cur-
rent axis 1 psychiatric disorder. The patient and control samples
were matched on the mean, variance, and shape of distribu-
tions of age and education and the distribution of sex.
Prior to baseline assessment, patients and controls were with-
drawn or refrained from all CNS-active medication and alcohol
intake for at least 14 days, with the exception of medication for
sleep such as lorazepam or zolpidem, for which the period was
at least 7 days. Fluoxetine had to be discontinued at least 6 weeks
prior to the baseline assessment. The afternoon before the PET
and MRI procedures, patients and controls were admitted to the
General Clinical Research Unit at the Columbia University Medi-
cal Center. Their diet was caffeine-free from admission until
completion of the evaluations. Subjects did not smoke during the
12 hours prior to PET assessment.
All participants provided written informed consent, and the
study was approved by the institutional review boards of the New
York State Psychiatric Institute and Columbia University.
ASSESSMENT PROCEDURES
In addition to the imaging procedures, patients and controls
underwent extensive cognitive, neurologic, rheumatologic, and
psychiatric examinations. The cognitive assessments sampled
6 domains: attention (Stroop task; Continuous Performance
Test), memory (Buschke Selective Reminding Test [verbal
memory]; Benton Visual Retention Test [visual memory]), mo-
tor function (simple reaction time; choice reaction time; fin-
ger tapping), working memory (N-Back Test; A, Not B Logical
Reasoning Test), psychomotor function (Trail Making A&B;
Digit Symbol), and verbal fluency (Controlled Oral Word As-
sociation Test; Category Fluency Test). These measures are de-
scribed elsewhere.18,19 Using either published norms or a ref-
erence sample of healthy controls, scores on these tests were
z-transformed and adjusted for the effects of sex, age, and edu-
cation. Each domain score represented the average of the z scores
for the primary tests within that cognitive domain. Overall per-
formance was characterized by averaging the 6 domain scores
to produce a cognitive index score. The neurological exami-
nation, which assessed 5 areas (sensory, motor, cranial nerves,
reflexes, and associated motor [cerebellar and basal ganglia]
functions) resulted in a summary score (range, 0-5) reflecting
the number of areas with at least 1 minor or major abnormal
finding. The rheumatologic examination assessed the number
of joints in pain either at rest or while in motion. Participants
also completed the Beck Depression Inventory-II (BDI-II),20 Zung
Anxiety Scale,21 Symptom Checklist–90,22 Fatigue Severity
Scale,23 McGill Pain Scale,24 and Medical Outcomes Study Short
Form–3625 after the medication-free period. On the basis of a
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medical history, a cardiovascular disease (CVD) risk factor score




The H215O and 2-deoxy-2-(18F)-D-glucose (FDG) (radioac-
tively labeled water and glucose, respectively) were synthe-
sized in a CTI computer-controlled chemistry process control
unit (CTI Inc, Knoxville, Tennessee). Scans were performed
with the Siemens ECAT EXACT HR (New York, New York).
A 20-gauge Teflon catheter was inserted into the radial artery
after examining for adequate collateral perfusion. The patient
was then positioned in a fixed head-holding device and a 15-
minute transmission scan was collected. Each rCBF measure-
ment consisted of a bolus injection of 12 to 15 mCi of H215O,
followed by a 10-mL saline flush. After tracer arrival in the brain,
a count-triggered 90-second emission scan (composed of three
30-second frames) was obtained in 3-dimensional mode. Ar-
terial blood was withdrawn at a constant rate via an auto-
mated peristaltic pump and radioactivity was recorded. The scans
were reconstructed using standard back-projection, filtering,
and measured attenuation. Quantification of CBF (in millili-
ters per minute per 100 g) followed the autoradiographic tech-
nique.27 For both CBF and CMR, absolute quantification was
obtained by submitting the time-activity curves to the algo-
rithms of the commercial PMOD software program (PMOD
Technologies Ltd, Zurich, Switzerland). There was a 15-
minute interval between serial injections.
Functional imaging scans commenced at the same time of
day for all participants (9:30 AM). Urine for toxicology was ob-
tained earlier that morning. Admission to the General Clinical
Research Unit the previous afternoon ensured dietary control.
The first oxygen 15 (15O) scan was during an eyes-open, ears-
unoccluded, resting condition (rest: room air). The only au-
ditory stimulation was the background machine noise. Rest-
ing instructions were given 3 minutes before injection. This
measurement was followed by a second resting assessment also
under room air conditions, but with a mouth snorkel in place
(rest: snorkel). This condition functioned as a control both for
the first rest: room air assessment (same air) and for the hy-
percapnic challenge (same breathing apparatus). The third as-
sessment involved hypercapnic challenge. Participants breathed
5% carbon dioxide (CO2) mixed in the air from a tank through
the snorkel. The CO2 mixture was administered for 3 minutes
prior to the 15O injection and continued throughout the scan.
For each 15O scan, arterial blood sampling for PaCO2 was ob-
tained prior to and following the assessment. Peak values were
used to characterize the blood gas level during the measure-
ment. Inhalation of CO2 was chosen over administration of ac-
etazolamide, given the more rapid onset and reversibility of hy-
percapnic effects with CO2, the utility of PaCO2 monitoring, and
uncertainty about the mechanisms of acetazolamide.28 The FDG
scan was performed after the 3 rCBF measurements.
FDG Positron Emission Tomography
The CMR for glucose was assessed during an eyes-open rest-
ing condition, with instructions for rest given 3 minutes prior
to injection of 5 mCi of FDG. Forty minutes were allowed for
uptake and equilibration, followed by a 60-minute PET scan
composed of twelve 5-minute frames (3-dimensional acquisi-
tion). Arterial samples were repeatedly drawn by pump to de-
rive a time-activity curve and to verify that blood glucose was
stable. The scanning procedure resulted in greater than 60 mil-
lion total counts. Each frame was reconstructed with standard
filtered back-projection routines to a resolution of approxi-
mately 7 mm full width half maximum. Measured attenuation
factors were used for all reconstructions. The frames were math-
ematically aligned and summed. For FDG, quantification was
performed using the Sokoloff autoradiographic method as modi-
fied by Phelps.29
Magnetic Resonance Imaging
Magnetic resonance images were acquired using a dedicated
1.5-T GE Signa Advantage system (Chalfont St Giles, En-
gland). The PET and MRI data were coregistered to the T1-
weighted spoiled gradient recalled images.30 Results of the MRI
analyses will be reported in a separate article.
STATISTICAL ANALYSIS
Analytic Strategy
Except where otherwise indicated, the patient and control groups
were compared using analyses of covariance (ANCOVAs), with
diagnostic group (patient vs control) as the between-subject
factor and the 3 matching variables age, sex, and education as
covariates. When significant effects of diagnostic group were
obtained, the American Health Association (AHA) CVD risk
factor score was added as an additional covariate to examine
whether effects persisted once controlling for this factor. To
explore whether differences in rates of current depressive dis-
order or severity of depressive symptoms were responsible for
the between-group differences, additional secondary analyses
were performed. One set excluded those patients who met
DSM-IV criteria (n=8) for a current episode of any depressive
disorder from the comparisons of the patient and control groups.
Another set of secondary analyses added the BDI score to the
standard set of covariates to determine whether the between-
group differences persisted after controlling for the severity of
depressive symptoms. All tests were 2-tailed and=.05 was used
to determine statistical significance.
Global Effects
For each individual, the functional images were warped into a
common probabilistic space. This routine coregistered the PET
images to an MRI template derived from the structural images
of an independent sample of control participants. The voxels
in the probabilistic space had previously been identified as rep-
resenting gray or white matter using an automated segmenta-
tion algorithm, and average CBF and CMR values were calcu-
lated for these tissue types. The ANCOVAs were conducted
comparing the Lyme disease and control groups in global gray
matter CBF and CMR values.
Distribution of Topographic Differences
Previous imaging studies have suggested that patients with Lyme
disease show scattered abnormalities in CBF or CMR that may
appear in gray or white matter and for which location may not
be consistent across individuals. Marked but topographically in-
consistent deficits would be missed by standard analytic para-
digms, and we developed a new approach to address this issue.
All of the PET images were carefully checked for scan arti-
facts and were motion corrected. The images were registered
to Montreal Neurological Institute space as implemented by Sta-
tistical Parametric Mapping (SPM99; Wellcome Trust Center
for Neuroimaging at University College of London, London,
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England).31 The image intensity values of the controls at each
voxel were normalized so the mean at each voxel was 0 and
the standard deviation was 1. The distributions in the control
group were then imposed on the patient group using a stan-
dard z transformation. Thus, the globally normalized CBF or
FDG z statistic at each voxel reflected the extent of the differ-
ence from average in the control sample in units of standard
deviation. For each individual, the number of voxels were
counted that represented varying degrees of departure above
or below the average values for controls. In this way, the groups
could be compared in overall number of voxels with extreme
values regardless of location.
Traditional Topographic Analyses
The SPM99 software was used to examine differences be-
tween the patient and control groups in the topography of rCBF
and rCMR values. A Gaussian kernel of 11 mm full width half
maximum for 15O images and 7 mm full width half maximum
for FDG images was applied to spatially smooth the images.
Images of raw counts were used instead of quantified data and
normalized to the scan mean. The global mean across voxels
was proportionally scaled to 50 and the analysis threshold, ap-
plied to normalized data, was set to a 0.8 proportion of the global
mean. The overall height threshold for identifying potentially
significant clusters was set to P .01, with an extent threshold
of 25 voxels. A z value of 3.0 or greater was required for con-
sidering a cluster significant. As before, age, sex, and educa-
tion level served as covariates in all between-group analyses.
These thresholds reflected a conservative choice in identify-
ing areas of between-group significant difference. The avail-
ability of 2 resting rCBF measurements, an rCBF measure-
ment under hypercapnia, and a measurement of rCMR allowed
for determination of the reliability of the rCBF resting deficits,
their expression during hypercapnia, and coupling with meta-
bolic abnormalities.
RESULTS
At baseline, the patient and control groups did not dif-
fer in the matching variables, age, sex, and education level
(Table1). Nonetheless, the patient group reported more
severe pain and fatigue and greater impairment in physi-
cal function, performed worse on neurocognitive test-
ing, and, on examination, had more joints with pain and
more areas of neurologic abnormality. They also re-
ported greater severity of depression and anxiety and, by
DSM-IV diagnosis, presented with a higher rate of hav-
ing a current episode of a depressive disorder.
GLOBAL CMR AND CBF AT REST
The groups did not differ in estimates of resting global CMR
(Table 2) while controlling for age, sex, and education
level (F1,39=0.45; P=.65). The patient group had signifi-
cantly higher whole-brain CBF than the control group in
the initial resting condition (F1,40=7.28; P=.01), but not
in the subsequent snorkel (F1,34=2.58; P=.12) or hyper-
capnic (F1,28=0.09; P=.77) conditions. This same pattern
held when the whole-brain voxels were segmented into
gray and white matter tissue types and when the CVD risk
factor score was added as a covariate (data not shown).
The higher global CBF values in patients during the
first room air resting measurement may have reflected a








Age, y 44.9 (12.9) 44.9 (11.3) .99
Female, % 57.1 76.5 .17
Education, y 14.7 (2.6) 15.8 (2.3) .16
AHA CVD score 3.0 (2.5) 2.1 (1.9) .24
Duration of prior IV antibiotics, mo 2.1 (1.6)
Duration of prior oral antibiotics, mo 7.0 (9.4)
Duration of illness, mo 101.9 (75.0)
Current pain, McGill Visual Analog Scale 4.9 (3.3) 0.1 (0.2) .001
Fatigue severity scale 5.3 (1.4) 2.0 (0.5) .001
Physical components scale, SF-36 36.2 (8.3) 55.9 (3.7) .001
Mental components scale, SF-36 40.8 (11.4) 56.3 (3.0) .001
Beck Depression Inventory 11.9 (8.2) 2.0 (2.4) .001
Zung Anxiety Index 47.5 (10.8) 32.9 (6.9) .001
DSM-IV current depressive episode, No. 8 0 .04
Joints in pain at rheumatologic examination, No. 5.9 (5.5) 0.6 (0.7) .001
Neurological examination summary score 2.3 (1.4) 0.7 (1.0) .001
Neurocognitive status
Motor −0.21 (1.29) 0.59 (0.65) .005
Psychomotor −0.17 (0.71) 0.94 (0.75) .001
Attention −0.07 (0.96) 0.26 (0.78) .19
Memory −0.65 (1.02) 0.52 (0.40) .001
Working memory −0.63 (1.00) 0.29 (0.68) .001
Language −0.75 (0.80) 0.47 (0.68) .001
Overall index score −0.42 (0.62) 0.51 (0.38) .001
Abbreviations: AHA, American Heart Association; CVD, cerebrovascular disease; IV, intravenous; SF-36, Medical Outcomes Study Short Form-36.
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“first run” effect. When comparing global CBF during
the first room air and the subsequent snorkel condition,
the patient group showed a significant decrease (t26=2.79;
P .01), while the control group had no change
(t10=−0.26; P=.80). During a secondary analysis, when
the patients with a current diagnosis of a depressive dis-
order (n=8) were excluded, the between-group differ-
ence in global CBF during the first resting measurement
was no longer significant (F1,32=1.75; P=.19). When BDI




The patient group showed diminished hypercapnic re-
activity when the first resting measurement was used as
the baseline. The 23 patients who had fully quantified
resting and hypercapnic measurements had a mean (SD)
decrease of 3.82% (14.21%), while 9 controls showed an
increase of 32.31% (45.58%) (F1,27=7.27; P=.01). How-
ever, as noted earlier, CBF in patients was elevated at the
first compared with the second measurement. Nonethe-
less, when the second measurement (snorkel condi-
tion) was used as the baseline, the 23 patients contin-
ued to show diminished hypercapnic reactivity
(mean[SD],8.28%[15.84%]) compared with 7 controls
(mean [SD], 28.12% [35.36%]; F1,25=6.47; P .02).
The diminished hypercapnic reactivity in the patient
sample could not be attributed to differences in CO2 in-
halation, as reflected in blood gas values. The 2 groups
did not differ in peak PaCO2 values during any of the 3
measurements, nor in the percentage of change in these
values during hypercapnia relative to the 2 earlier mea-
surements (all P .09). The diminished reactivity in
the patient sample remained significant (both P .01)
when the percentage of change in PaCO2 was added as a
covariate to the ANCOVAs on the percentage of change
in CBF during hypercapnia relative to either of the pre-
ceding resting measurements. Excluding patients with
a current diagnosis of a depressive disorder or adding
BDI or AHA CVD scores as a covariate did not alter
these patterns.
DISTRIBUTION OF EXTREME VALUES
The patient and control groups did not differ in re-
peated measures ANOVA on the distribution of CMR
z scores for gray matter voxels (Figure1) (F2.08,93.57=1.21;
P=.30). Although the distribution for patients was shifted
slightly to the left, suggesting a larger number of voxels
with reduced CMR, this analysis indicated that, inde-
pendent of topography, there was not an excess of vox-
els with low or high CMR in either group across all brain
regions. The same pattern occurred in all of the CBF analy-
ses (Figure 1), none of which yielded an interaction be-
tween diagnostic group and z score bin (all P .18). In
contrast, the z bin analyses consistently yielded signifi-
cant effects of age, sex, and education level (P .05).
Whole-brain z bin distributions were also consistently
found to be a function of the CVD risk factor score when
this score was added as an additional covariate (P .05).
TOPOGRAPHIC ANALYSES
FDG Rest
Based on a sample of 33 patients and 17 controls, 12 clus-
ters involving 3049 voxels were identified in the SPM co-
variance analysis with patients having lower FDG than
controls (Table 3; Figure 2). There were 3 clusters,
involving 680 voxels, where CMR was higher in pa-
tients than in controls. The FDG regional pattern had no-
table similarity to the group differences in CBF (see be-
low). Across the CMR and CBF analyses, there were widely
distributed reductions in left prefrontal and bilateral pos-
terior gray and white matter areas. The largest clusters
of reduced CMR in patients were located in the left tem-
poral and frontal areas as well as the right cingulate. No-
tably, there was little evidence of CMR reduction in pa-
tients in the right prefrontal cortex; this was mirrored
in the CBF analyses. Of the 3 clusters showing in-
creased CMR in patients, the ones in the right occipital
lingual gyrus and the right frontal gyrus were also seen
in the CBF conditions (Figure 2). Contrary to the CBF
analyses, a relative CMR increase was also observed in
patients in the left insula. In addition to the main effects
Table 2. Brain Imaging Global Values
Variable
Mean (SD)
P ValuePatients With Lyme Disease Controls
Total sample
CMR, resting (n=31, 13) 3.25 (1.91) 3.83 (2.30) .65
CBF, resting: room air (n=31, 14) 45.51 (5.85) 38.77 (11.69) .01
CBF, resting: snorkel with room air (n=28, 11) 41.61 (6.92) 40.34 (13.81) .12
CBF, hypercapnia (n=24, 9) 45.06 (6.60) 45.83 (9.22) .76
Subsample of patients who had hypercapnia
CMR, resting (n=23, 8) 2.88 (1.83) 3.58 (1.81) .41
CBF, resting: room air (n=23, 9) 45.69 (6.43) 37.64 (13.67) .02
CBF, resting: snorkel with room air (n=23, 7) 41.81 (7.35) 38.62 (14.83) .05
CBF, hypercapnia (n=24, 9) 45.06 (6.60) 45.83 (9.22) .76
Abbreviations: CBF, cerebral blood flow in units of milliliters per minute per 100 g; CMR, cerebral metabolic rate in units of milligrams per minute per 100 g.
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of diagnostic group, there were marked main effects of
each of the covariates on CMR. Excluding patients with
a current diagnosis of a depressive disorder or adding BDI
or AHA CVD scores as a covariate did not alter these pat-
terns. Lower CMR in widespread regions was associated
with advanced age (9 clusters, 19 539 voxels), male sex
(19 clusters, 5649 voxels), and fewer years of education
(11 clusters, 2103 voxels). There were few significant clus-
ters opposite in direction.
CBF Rest: Room Air Condition
The SPM covariance analysis contrasting patients (n=35)
and controls (n=17) yielded 9 clusters involving 2828
voxels, where CBF was greater in controls than in pa-
tients (Table 3; Figure 2). Patients had higher CBF than
the control group in only 1 cluster, involving 222 vox-
els. The CBF reductions in patients pertained to both cor-
tical gray matter structures and underlying white mat-
ter and were mainly distributed in left frontal (Brodmann
area [BA] 10) and bilateral temporal and occipital re-
gions. In particular, the right prefrontal cortex ap-
peared to be spared or elevated in the patients with Lyme
disease, while bilateral posterior and left parahippocam-
pal areas were most affected. The 1 area of increased CBF
in patients relative to controls was in the right medial fron-
tal gyrus (BA 10).
CBF Rest: Snorkel Condition
Data were available for 29 patients and 14 controls. An SPM
subtraction analysis was conducted contrasting CBF pro-
files in the resting snorkel and preceding resting room air
conditions. A highly circumscribed pattern was observed
across and within the diagnostic groups. Cerebral blood
flow was markedly higher in the snorkel condition in the
left and right sensorimotor cortices. There were no CBF
increases in the room air relative to the snorkel condition.
This indicated that the principal effect of the snorkel con-
dition was to increase CBF in primary sensorimotor areas,
presumably reflecting stimulation of the mouth. Effec-
tively, with this difference aside, the snorkel condition could
be considered a second resting measurement.
To determine whether the pattern of baseline topo-
graphic abnormalities was consistently observed across the
measurement conditions, an SPM analysis was conducted
contrasting patients and controls, restricting the data to the
snorkel condition. There were 9 clusters involving 2363
voxels in which patients had lower CBF than controls
(Table 3). Inspection of Figure 2 suggested that the pat-
tern of CBF abnormality in patients was similar in the snor-
kel and room air conditions. There were only 2 significant
clusters, involving 240 voxels, in the opposite direction.
CBF Hypercapnia
Data from the hypercapnic manipulation were available
for 24 patients and 10 controls. As in the analysis of the
snorkel condition, there was a marked bilateral increase
in sensorimotor cortex when the hypercapnic and first
resting room air condition were contrasted, with no
change in topography when the hypercapnic and snor-
kel conditions were compared. Thus, relative to the first
room air condition, the major topographic change in the
2 subsequent conditions reflected activation of the sen-
sorimotor cortex, presumably due to motor and sensory
































































 Patients with Lyme disease
Figure 1. Distribution of voxels by z bin scores in patients with Lyme disease
and healthy volunteers (controls). Distribution is for measurement of
cerebral metabolic rate for glucose (A) and for the first resting (room air)
measurement of cerebral blood flow (CBF) (B). The z bins were determined
by the distribution of values for gray matter in the control sample. While the
patient group is shifted slightly to the left of the controls, there were no
significant differences between the groups in z bin distributions for any
assessment. FDG indicates 2-deoxy-2-(18F)-D-glucose.
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Table 3. Clusters in Which Patients With Lyme Disease Differed From Controls in CMR or CBFa
MNI Coordinates
Voxel,
No. z Scorex y z
CMR rest,  patients
Left temporal, superior temporal gyrus, WM (GM, BA 22, distance=3) −54 −50 24 531 4.07
Right parietal, inferior parietal lobule, WM (GM, BA 40, distance=3) 56 −40 32 265 3.51
Left temporal, middle temporal gyrus, WM (GM, BA 39, distance=2) −46 −70 32 334 3.43
Left frontal, superior frontal gyrus, WM (GM, BA 8, distance=2) −18 46 46 62 3.41
Left sublobar, extranuclear, WM (GM, claustrum, distance=2) −34 22 −2 439 3.40
Right limbic, posterior cingulate, GM, BA 30 24 −64 16 178 3.35
Left frontal, subgyral, WM (GM, BA 6, distance=3) −34 −8 46 527 3.30
Right sublobar, insula, GM, BA 13 52 4 −2 154 3.21
Left parietal, precuneus, GM, BA 7 −12 −54 72 36 3.07
Right limbic, cingulate gyrus, GM, BA 24 4 8 44 309 3.03
Left cerebellum, anterior lobe, fastigium, GM −6 −48 −22 75 3.02
Left parietal, posterior central gyrus, WM −58 −14 22 139 3.01
CMR rest, patients  controls
Left sublobar, extranuclear, WM (GM, BA 13, distance=1) −36 −6 26 172 4.08
Right occipital, lingual gyrus, WM (GM, BA 18, distance=3) 14 −82 2 316 3.29
Right frontal, superior frontal gyrus, WM (GM, BA 9, distance=4) 20 52 18 192 3.14
CBF room air, controls  patients
Left temporal, supramarginal gyrus, WM (GM, BA 39, distance=1) −60 −52 32 149 3.61
Right occipital, middle occipital gyrus, WM (GM, BA 19, distance=2) 42 −86 24 155 3.54
Left frontal, superior frontal gyrus, GM, BA 10 −12 70 8 123 3.45
Left occipital, subgyral, WM (fusiform, GM, BA 37, distance=2) −48 −58 −6 525 3.43
Right temporal, superior temporal gyrus, GM, BA 22 58 −6 2 556 3.40
Left limbic, parahippocampal gyrus, WM (GM, BA 36, distance=1) −40 −26 −14 883 3.32
Right limbic, posterior cingulate (GM, BA 31, distance=3) 20 −66 20 212 3.29
Right middle occipital gyrus, (GM, BA 19, distance=2) 58 −74 8 126 3.19
Left midoccipital gyrus, WM (limbic, posterior cingulate, GM, BA 30, distance=4) −32 −70 24 99 3.08
CBF room air, patients  controls
Right frontal, medial frontal gyrus, WM (GM, BA 10, distance=2) 18 52 2 222 3.05
CBF snorkel, controls  patients
Left parietal, postcentral gyrus, WM (GM, BA 40, distance=1) −66 −18 22 367 4.10
Right temporal, superior temporal gyrus, GM, BA 22 52 −14 0 646 3.66
Left limbic, cingulate gyrus (GM, BA 24, distance=1) −2 −2 42 335 3.45
Right frontal, middle frontal gyrus, GM, BA 9 50 28 36 114 3.29
Left frontal, superior frontal gyrus, WM (GM, BA 8, distance=1) −18 40 52 77 3.29
Left cerebellum anterior lobe, culmen, GM −40 −54 −22 569 3.24
Right frontal, middle frontal gyrus, WM (GM, BA 47, distance=2) 56 44 −10 92 3.20
Left frontal, subgyral, WM (limbic, cingulate gyrus, GM, BA 31, distance=4) −22 −20 40 90 3.03
Right temporal, transverse temporal gyrus, WM (GM, BA 41, distance=2) 42 −30 14 73 3.03
CBF snorkel, patients  controls
Right occipital, lingual gyrus, GM, BA 18 12 −80 −4 167 3.50
Right frontal, subgyral, WM (limbic, anterior cingulate, GM, BA 32, distance=3) −18 −34 2 73 3.18
CBF hypercapnia, controls  patients
Right cerebellum, posterior lobe, declive, GM 54 −74 −20 393 4.85
Left limbic, parahippocampal gyrus, WM (GM, BA 36, distance=2) −38 −28 −12 539 3.91
Left limbic, posterior cingulate, WM (GM, BA 30, distance=3) −10 −48 22 245 3.83
Left frontal, middle frontal gyrus, GM, BA 6 −40 −4 52 1086 3.80
Left parietal, precuneus WM (superior parietal GM, BA 7, distance=4) −24 −54 48 1132 3.74
Right sublobar, extranuclear WM (insula, GM, BA 13, distance=3) 42 −24 8 1515 3.59
Left occipital, cuneus, GM, BA 19 −24 −90 34 171 3.56
Left temporal, fusiform gyrus, GM, BA 37 −58 −62 −12 814 3.55
Right frontal, middle frontal gyrus, GM, BA 6 34 4 52 750 3.53
Left parietal, superior parietal lobule, GM, BA 7 −4 −64 70 189 3.44
Left parietal, postcentral gyrus, GM, BA 40 −66 −22 22 115 3.43
Left limbic, cingulate gyrus, WM (GM, BA 23, distance=2) −6 −6 36 812 3.30
Right temporal, subgyral WM (superior temporal gyrus, GM, BA 13, distance=4) 50 −46 32 545 3.26
Right limbic lobe, posterior cingulate, GM, BA 30 22 −64 44 209 3.19
Left inferior parietal lobule, WM (posterior central gyrus, GM, BA 5, distance=2) −40 −42 66 74 3.05
CBF hypercapnia, patients  controls
Right medial frontal gyrus, WM (superior frontal gyrus, GM, BA 10, distance=1) 20 58 −6 224 3.46
Abbreviations: BA, Brodmann area; CBF, cerebral blood flow; CMR, cerebral metabolic rate; GM, gray matter; MNI, Montreal Neurological Institute; WM, white matter.
aNearest GM is marked in parentheses next to the WM along with the distance in millimeters and Brodmann area.
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When the SPM analysis was conducted solely on the data
from the hypercapnic condition, there were 15 clusters in-
volving 8589 voxels in which patients had lower CBF than
controls. The pattern of CBF abnormality in patients was
amplified relative to either of the prior resting measure-
ments. Inspection of Figure 2 suggested that the abnor-
malities observed under the resting conditions were ex-
pressed more widely with the hypercapnic manipulation
as opposed to involving a new pattern of deficits. There was
only 1 significant cluster in the opposite direction, involv-
ing 224 voxels, with patients showing higher relative CBF
in the right superior frontal gyrus gray matter.
CBF Analyses: Covariates
As in the CMR analysis, each SPM analysis contrasting
the patient and control groups in the 3 CBF conditions
used age, sex, and education as covariates. Each of these
analyses yielded marked effects for each covariate. For
example, in the first resting measurement, advanced
age (10 clusters, 18 492 voxels), male sex (19 clus-
ters,14 655 voxels), and fewer years of education (8 clus-
ters, 2922 voxels) were each associated with widely dis-
tributed CBF reductions. There were few significant effects
in the opposite direction. These effects were also highly
consistent with the CMR findings. The between-group
differences observed in each of the CBF conditions were
essentially unaltered when excluding patients with a cur-
rent diagnosis of a depressive disorder or adding the BDI
or AHA CVD score as an additional covariate.
COMMENT
This study examined the differences in CBF and CMR be-
tweendemographicallymatchedcontrolsandpatientswith
objectivecognitiveabnormalitieswhohadawell-documented
history of Lyme disease that had been previously treated
withat least3weeksof intravenousantibiotictherapy.These
patients reported that their cognitive symptoms emerged
aftercontractingLymediseaseandthattheirsymptomseither
returned or persisted despite prior treatment. Prior reports
had suggested that patients with later-stage Lyme disease
havepatchyhypoperfusionintheCNSthat issimilar towhat
onewouldsee inaconditionresulting inCNSvasculitis.10,32
This patchy hypoperfusion could reflect either a true vas-
culitic process or an alteration in vascular demand as a re-
sult of diffuse and scattered metabolic deficits.
TheSPManalysesrevealedthat,comparedwithcontrols,
the patients had substantial differences in specific brain re-
gions of blood flow and metabolism. There were only a few
areas involvingarelativelysmallnumberofvoxels inwhich
patients showed higher CBF or CMR than controls—
specifically, the right frontal gyrus (BA 9 and BA 10). On
the other hand, many areas showed lower CBF and CMR
in the patient group—specifically, bilateral gray and white
matter in temporal, parietal and limbic regions and the left
frontal cortex (Table 3; Figure 2). These findings are con-
gruentwithpriorarticles thatdescribedhypofunction,par-
ticularly in the temporal area, in patients with Lyme
disease.11-13 Notably in this study, deficits were rare in the
Patients < healthy participants
FDG
    CBF:
Resting 1
    CBF:
Resting 2
    CBF:
Hypercapnia
Patients > healthy participants
Figure 2. Statistical Parametric Mapping images of cerebral brain metabolism and blood flow (CBF) under 3 conditions: resting 1 indicates room air; resting 2,
room air with snorkel; hypercapnia, room air enhanced with carbon dioxide with snorkel. Patients have multiple areas of decreased metabolism and blood flow
that, for the flow, are enhanced under hypercapnia. There are very few areas where patients had increased metabolism or flow compared with the controls. FDG
indicates 2-deoxy-2-(18F)-D-glucose.
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right frontal cortex.Manyof theareasofabnormalCBFand
CMRidentified inTable3havebeenassociatedwithsymp-
tom complexes common to patients with Lyme encepha-
lopathy including problems with language fluency (BA 22,
39, and 40), executive functioning and working memory
(BA 9 and 10), memory encoding and retrieval (BA 10, 30,
and 36), visual attention (BA 19), spatial orientation (BA
7), emotional processing of pain (BA 13), and regulation
of autonomic function and rational cognition (BA 24).
Compared with controls, the patients with Lyme en-
cephalopathy did not have a randomly scattered excess of
either extreme hyperfunction or hypofunction in either ce-
rebral blood flow or metabolic rate. Although the analytic
method we developed was sensitive to demographic fac-
tors such as age and sex that diffusely affect CBF and/or
CMR, there was no evidence in this study that the patient
group was characterized by an excess of extreme values.
These findings suggest that a distributed network or set
ofnetworks is abnormal in individualswhohavepersistent
symptoms after conventional treatment of Lyme disease.
Rather than a randomly scattered distribution of heteroge-
neous hypoperfusion that varies significantly from person
toperson, thedeficitswere sufficiently largeandconsistent
inthepatientgroupforSPMtorevealmultipleregionswhere
patients had lower CBF and CMR and a much smaller set
of deficits where patient CBF and CMR exceeded controls.
Furthermore, theconsistencyof thesedeficitsacross4mea-
suresofbrain function(1CMRand3CBF)supports the re-
liability of the findings and the notion that a uniform dis-
ease process was responsible for the abnormalities.
There was little evidence in this study to suggest that
patients had a global deficit in resting blood flow or me-
tabolism. Although the first resting room air CBF mea-
surement revealed a global increase in the patient sample,
this difference did not persist through the second resting
room air: snorkel measurement. Higher global functional
activity is often seen in a first resting measurement rela-
tive to subsequent measurements and has usually been at-
tributed to the greater emotional reactivity with the initial
measurement.33,34 Supporting the hypothesis that measure-
ment anxiety may have accounted for the higher CBF seen
at the first but not the second measurement was the ob-
servation that an elevated measurement during the first rest-
ing procedure was no longer noted when the 8 patients with
a comorbid depressive disorder were excluded.
When either the first or second resting CBF condition
was used as a baseline to assess the CBF response to the
hypercapnic challenge, the patients showed diminished va-
sodilation relative to the control group. Diminished vaso-
dilation may occur because perfusion pressure is already
maximal or because the vasculature is otherwise compro-
mised. Some of the dysfunction in neurologic Lyme dis-
ease may result from inflammatory changes in CNS blood
vessels—a hypothesis supported by case reports of diffuse
or focal vasculitides and strokes35-37 attributed to Lyme dis-
ease and by perivascular inflammation noted in brain bi-
opsies of patients with Lyme disease.38 However, while the
results suggest that a vascular disease process was active
in the patient sample, the patients and controls did not dif-
fer in global CBF during the hypercapnic assessment. The
observation of a hypercapnic deficit in patients was likely
owing to higher absolute global values in the patient groups
in the 2 prior resting measurements, although this differ-
ence only achieved statistical significance for the first rest-
ing measurement. Furthermore, the deficits seen during hy-
percapnia, while broader and more extensive than those
seen during any of the other CBF or CMR measurements,
did not reflect a change in pattern as much as a widening
of the boundaries of the areas of deficits observed in the
other CBF and CBF assessments (Figure 2). These obser-
vations suggest that there was strong coupling between the
CBF and CMR deficits and that the regional abnormalities
observed in this study were primarily metabolically driven.
The few controlled MRI studies of posttreatment Lyme
disease are consistent with the impression that the persis-
tent brain effects are not primarily due to structural vascu-
lardisease.OneMRIstudy9thatusedT1,T2,fluid-attenuated
inversionrecovery,anddiffusion-weightedimagingsequences
found no significant difference in the number of structural
abnormalities in patients with posttreatment Lyme disease
compared with age- and sex-matched controls and no re-
lationship with the number of lesions and the duration of
disease.AsecondMRIstudy39foundnodifferenceinthemean
or peak magnetization transfer ratio between patients with
posttreatmentLymediseaseandcontrols, indicatingthat the
multifocalperfusiondeficitspreviously reportedonSPECT
imaging and now demonstrated with PET imaging are not
associated with detectable structural damage.
This study does not address whether the imaging ab-
normalities reflected persistent B burgdorferi infection as
opposed to a postinfectious process. We also cannot prove
that the imaging abnormalities might not be accounted for
by another unexamined variable in which the groups dif-
fered. For example, we examined whether depression might
have accounted for the differences because it is well known
that depression is associated with functional imaging ab-
normalities.40-42 In this case, the functional imaging find-
ings were unaltered when individuals with depressive co-
morbidity were removed from the patient sample or when
scores on the BDI were used as a covariate. Similarly, the
findings were unaltered after controlling for cerebrovas-
cular disease risk factor scores. Finally, although patients
reported developing cognitive problems only after getting
Lyme disease, we cannot be certain that the identified brain
regional abnormalities were not present prior to infec-
tion. The consistency of the regionally specific abnormali-
ties in CBF and CMR, however, support the likelihood that
the observed dysfunction reflects a unitary etiology that re-
sulted in either sustained damage from prior infection with
B burgdorferi or an ongoing CNS disease process.
The areas of prominently reduced metabolism and blood
flow in our study were the temporal-parietal and limbic areas
bilaterally as well as the left frontal cortex. The results of
this study are congruent with clinical series that have de-
scribed multifocal areas of hypofunction in both cortical
and subcortical white matter, particularly in the temporal
lobes.11-13 Although helpful in confirming objective cen-
tral nervous system abnormalities in a patient with a his-
tory of Lyme disease, this pattern of hypofunction is non-
specific and cannot be used to make the diagnosis of Lyme
encephalopathy. Indeed, a pattern of multifocal cortical and
subcortical hypofunction can occur from other causes as
well, such as chronic cocaine use, human immunodefi-
ciency virus infection, and systemic lupus erythematosus.
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In conclusion, this study demonstrates that patients
with persistent encephalopathy after treatment for Lyme
disease have objective neurobiological dysfunction.
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